Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis

Background: The first- and second-trimester screening for trisomy 21 (T21) are reimbursed for all pregnant women in Belgium. Using a cut-off risk of 1: 300 for T21, about 5% of all pregnant women are referred for definitive prenatal diagnosis using an invasive test, at a sensitivity of (only) 72.5%. The sensitivity and specificity of the non-invasive prenatal test (NIPT) are over 99% but come at a cost of (sic)460 (373) pound per test. The objective is to estimate the consequences of introducing NIPT for the detection of T21. Methods: A cost-consequences analysis was performed presenting the i... Mehr ...